1RCT2006
Skorokhodov AP, Dudina AA, Kolesnikova EA, Koron AE, Kobantsev IuA, Sedova AA · Zh Nevrol Psikhiatr Im S S Korsakova (2006)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
17 peer-reviewed studies
What the evidence says
Most Cortexin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1999–2026 with a typical study size of 110 participants.
Based on 17 studies · 1 meta-analysis · 10 RCTs · 110 total participants
Confidence
Moderate confidenceBy outcome
4 studies in the last 5 years · Latest meta-analysis: 2021
Skorokhodov AP, Dudina AA, Kolesnikova EA, Koron AE, Kobantsev IuA, Sedova AA · Zh Nevrol Psikhiatr Im S S Korsakova (2006)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Fedin AI, Belskaya GN, Kurushina OV, Kovalchuk VV, Starych EV, Chichanovskaya LV · Zh Nevrol Psikhiatr Im S S Korsakova (2018)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Shabanov PD, Vostrikov VV, Bushkova NV, Kuzenbaeva LB, Pavlenko VP, Mokeeva EG · Voen Med Zh (2007)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Skoromets AA, Stakhovskaia LV, Belkin AA, Shekhovtsova KV, Kerbikov OB, Burenchev DV · Zh Nevrol Psikhiatr Im S S Korsakova (2008)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Solov'ev AG, Elistratova TV · Zh Nevrol Psikhiatr Im S S Korsakova (2010)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Khavinson VKh, Morozov VG, Rybnikov VIu, Zakutskiĭ NG · Klin Med (Mosk) (1999)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Levchuk LA, Ivanova SA, Semke VY · Bull Exp Biol Med (2013)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Aliferova VM, Dadasheva MN, Doronin BM, Kovalenko AV, Lokshtanova TM, Martynov MIu · Zh Nevrol Psikhiatr Im S S Korsakova (2014)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: The domestic drug Cortexin is one of the most promising drugs for further clinical trials.
Putilina MV. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)
In plain English: Conclusion The comprehensive therapy with Cortexin proved to be highly effective, safe, and well-tolerated in patients with neurological complications of T2DM, and it is recommended for use in general clinical practice.
· Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026)
In plain English: The limited number of eligible studies for Actovegin (n = 2 trials,563 participants) and Cortexin, (n = 1 trial,80 participants) precluded meta-analyses but data suggested potential efficacy and no safety concerns.
Alsulaimani RA, Quinn TJ. · Cereb Circ Cogn Behav (2021)
In plain English: Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®; in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment.
Zhang L, Chopp M, Wang C, Zhang Y, Lu M, Zhang T, Zhang ZG. · J Neurol Sci (2019)
In plain English: Cortexin® (10 μg/ml) demonstrated high or moderate binding to AMPA-receptors (80.1%), kainate receptors (73.5%), mGluR1 (49.0%), GABAA1 (44.0%) and mGluR5 (39.7%).
Kurkin DV, Bakulin DA, Morkovin EI, Kalatanova AV, Makarenko IE, Dorotenko AR, Kovalev NS, Dubrovina MA, Verkholyak DV, Abrosimova EE, Smirnov AV, Shmidt MV, Tyurenkov IN. · PLoS One (2021)
In plain English: It was noted more rapid and complete regression of cognitive disorders in patients of the 1st and 2nd groups, in comparison with patients of the 3rd group.
Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsjannikova AN. · Zh Nevrol Psikhiatr Im S S Korsakova (2016)
In plain English: The most complete regression of neurological deficits and manifestations of cardiac autonomic neuropathy during the acute period of ischemic stroke was observed in the group of patients treated with cortexin.
Mashin VV, Belova LA, Aizatullin IF, Pavlova VA, Slasten EV, Abramova VV, Belov DV. · Zh Nevrol Psikhiatr Im S S Korsakova (2019)
In plain English: A decrease in NR2-peptide concentration (from 8.5 to 5.9 ng/ml, p<0.0001) was noted in patients treated with cortexin after 10-day treatment course.
Dambinova SA, Aliev KT, Bondarenko EV, Ponomarev GV, Skoromets AA, Skoromets AP, Skoromets TA, Smolko DG, Shumilina MV. · Zh Nevrol Psikhiatr Im S S Korsakova (2017)
In plain English: The use of cellex in comparison with cortexin is more effective in terms of the dynamics of regression of neurological and neurocognitive dysfunctions in patients with ERPIS.
Khabirov FA, Khaibullin TI, Granatov EV, Akhmetova GI, Akhmetzyanov NM. · Zh Nevrol Psikhiatr Im S S Korsakova (2020)